Aposcience AG products

Aposcience - Focus Wound Healing

Aposcience AG has found that the mixture of active components secreted from cultured apoptotic peripheral white blood cells (PBMCs) has superior efficacy in promoting wound healing and skin regeneration. The products have this effect by stimulating migration of keratinocytes and fibroblasts into the wounded area, as well as by promoting neovascularization of the wound and improving blood and oxygen supply. The company expects that products derived from PBMCs will have a significant impact in the care for millions of patients who are afflicted by poorly healing wounds (diabetic foot ulcers, ischemic ulcerations, pressure ulcers) and therefore present a very important market opportunity. If efficacy can be demonstrated in clinical trials, a turnover of well over 1 billion Euros can be expected.

Pre-Clinical

The company`s systemic formulation (APO-1 (APOSEC^TM)) derived from peripheral white blood cells (PBMCs) has been evaluated in animal models of wound healing, stroke, spinal cord injury, and models of chronic and acute myocardial infarction.

Aposcience - Pre-Clinical

Peripheral White Blood Cells (PBMCs)

PBMCs driven into apoptosis through cellular stress have been shown to be highly potent in experimental wound healing, stroke, spinal cord injury, acute and chronic infarction models and prevention of ischemia reperfusion injury.

Aposcience - Focus Myocardial Infarction

Aposcience AG has identified APO-1 (APOSEC^TM), derived from the secretome of irradiated, apoptotic peripheral blood mononuclear cells (PBMCs) as superbly efficacious in reducing infarct size and maintaining left ventricular function in animal models of myocardial infarction (MI). These models tested MI with and without reperfusion, including one of ischemia and reperfusion. These data are predictive for the prevention of adverse remodeling following revascularization of an acute MI. The target population are those over 700,000 patients worldwide who undergo reperfusion treatment for acute ST-elevation myocardial infarction. If APO-1 (APOSEC^TM) proves effective in clinical trials, the market potential is estimated at 1 – 2 billion Euros annually.